Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.7100
-0.0400 (-5.33%)
At close: Apr 28, 2026
Lyra Therapeutics Revenue
In the year 2025, Lyra Therapeutics had annual revenue of $398.00K, down -74.05%. Lyra Therapeutics had revenue of $7.00K in the quarter ending December 31, 2025, a decrease of -96.65%.
Revenue
398.00K
Revenue Growth
-74.05%
P/S Ratio
3.34
Revenue / Employee
14.74K
Employees
27
Market Cap
1.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 398.00K | -1.14M | -74.05% |
| Dec 31, 2024 | 1.53M | -24.00K | -1.54% |
| Dec 31, 2023 | 1.56M | 195.00K | 14.31% |
| Dec 31, 2022 | 1.36M | 1.08M | 378.25% |
| Dec 31, 2021 | 285.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLyra Therapeutics News
- 11 days ago - Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 11 months ago - Lyra Therapeutics Transcript: Study Result - Transcripts
- 11 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga